Safety and Efficacy of Memantine for Multiple Sclerosis-Related Fatigue: A Pilot Randomized, Double-Blind Placebo-Controlled Trial Publisher Pubmed



Falsafi Z¹ ; Tafakhori A² ; Agah E^{3, 4} ; Mojarrad M⁵ ; Dehghani R^{6, 7} ; Ghaffarpour M² ; Aghamollaii V⁸ ; Mousavi SV^{3, 4} ; Fouladi Z³ ; Pourghaz B² ; Balali P³ ; Harirchian MH² Show Affiliations
Source: Journal of the Neurological Sciences Published:2020

Abstract

Background: Fatigue is one of the most common symptoms in patients with multiple sclerosis (MS). Currently, there is no approved medication for MS-related fatigue. Objective: In this study, we aim to evaluate the safety and efficacy of memantine for improving fatigue in patients with MS. Methods: This was a pilot randomized, double-blind, placebo-controlled clinical trial. Eligible patients with relapsing-remitting MS (RRMS) according to the McDonald criteria were randomized to receive either memantine (20 mg/day) or placebo and were assessed at baseline and three months after treatment. The change in the severity of fatigue was determined by the Modified Fatigue Impact Scale (MFIS). Results: Sixty-four patients were randomly allocated to the memantine (n = 32) and placebo (n = 32) groups. Sixteen patients in the memantine group and 24 patients in the placebo group completed the study. The mean [95% CI] absolute change in MFIS scores from baseline did not differ significantly between the memantine (−5.8 [−12.7 to 1.0]) and placebo (−4.0 [−10.6 to 2.7]) groups (between-group difference: −1.9 [−11.7 to 7.8], P = .702). No serious adverse events were reported, except for dizziness and sedation in four patients in the experimental arm, which resulted in discontinuation. Conclusion: This trial failed to prove any clinical efficacy of memantine for the management of MS-related fatigue. Although memantine was generally well-tolerated, adverse events were among the major causes of dropout in this study. © 2020